Current Research Studies

Epilepsy – Phase 1 Study of ABI-009 for Surgically-Refractory Epilepsy (RaSuRE)

Condition or Therapy:

Surgically refractory epilepsy



What is the goal of this study?

Seizures that are refractory to both medical and surgical therapy increase the risk of morbitiy and mortality in children with epilepsy. At this point in time, options for these children are sparse and suboptimal. We want to learn if ABI-009 is a safe and well-tolerated medication in children who have medically-refractory epilepsy and have failed epilepsy surgery, and if the addition of ABI-009 therapy to the current clinical standard of continued antiepileptic medications results in improved epilepsy control.

Who can join the study?

This study might be a good fit if your child:

  • is between 3 and 26 years old, and
  • has epilepsy that has not responded to surgical treatment.

To be eligible for this study, participants must have at least 8 seizures per month and can't be on systemic corticosteroids, anticancer therapy, immunosuppressive agents or other investigational drugs.

What will happen if my child takes part in this study?

If you choose to participate in this study, your child will be continued and observed on their preexisting, clinically perscribed antiepileptic drug (AED) regimen for 1 month. at the 1-month mark, your child will receive weekly ABI-009 intravenously at different dose levels for a total of 3 weeks. ABI-009 will then be discontinued and your child will be obesrved for an additional 3 months. 

Who can I contact for more information?

To learn more, call 206-987-1697 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Jason Hauptman